Literature DB >> 11292197

Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding.

A Casonato1, E Pontara, U P Vertolli, A Steffan, C Durante, L De Marco, F Sartorello, A Girolami.   

Abstract

Chronic renal failure often is associated with abnormal bleeding that may represent an important complication of this disorder. The hemorrhagic tendency currently is attributed to altered primary hemostasis, mainly platelet dysfunction. However, von Willebrand factor (vWF) also seems to be involved, even though the nature of its abnormalities is still controversial. To gain insight into the role of vWF in determining uremic bleeding, we studied 11 patients with stable, chronic renal failure. We found a significant increase in plasma factor VIII (FVIII), vWF:antigen (Ag), and vWF:ristocetin cofactor (Rco) levels, associated with a mean decrease in platelet vWF:Ag. Plasma vWF multimer pattern was characterized by increased representation of all oligomers in all patients, but five patients also showed a slight decrease in large vWF multimers. In addition, platelet vWF multimer pattern displayed a decrease in all components, especially those with high molecular weight. Despite normal bleeding time, collagen-induced platelet aggregation was defective in almost all patients, whereas vWF collagen binding capacity was normal. The levels of glycocalicin, the circulating fragment of glycoprotein Ib-IX, the major platelet vWF receptor, were also normal. In six patients who also were studied after initiation of dialysis, collagen-induced platelet aggregation was impaired further. Moreover, plasma vWF, and especially FVIII levels, were increased additionally, in association with a normalized platelet vWF content and an improved vWF multimer pattern. The results suggest that vWF abnormalities are present in uremia. Moreover, thrombopathy caused by impaired collagen-induced platelet aggregation is constantly present and apparently not improved by dialytic treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292197     DOI: 10.1177/107602960100700201

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  6 in total

1.  Patient-specific antithrombotic strategies: lessons not yet learned from the renal insufficiency paradigm.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

Review 2.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

3.  Von Willebrand factor as a thrombotic and inflammatory mediator in critical illness.

Authors:  William E Plautz; Zachary A Matthay; Marian A Rollins-Raval; Jay S Raval; Lucy Z Kornblith; Matthew D Neal
Journal:  Transfusion       Date:  2020-06-01       Impact factor: 3.157

4.  Thrombin-anti-thrombin levels and patency of arterio-venous fistula in patients undergoing haemodialysis compared to healthy volunteers: a prospective analysis.

Authors:  James A Milburn; Isobel Ford; Nicola J Mutch; Nicholas Fluck; Julie Brittenden
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

5.  Primary hemostatic function in dogs with acute kidney injury.

Authors:  Duana McBride; Rosanne E Jepson; Stefano Cortellini; Daniel L Chan
Journal:  J Vet Intern Med       Date:  2019-08-05       Impact factor: 3.333

6.  Coagulation Abnormalities in Renal Pathology of Chronic Kidney Disease: The Interplay between Blood Cells and Soluble Factors.

Authors:  Efthimia G Pavlou; Hara T Georgatzakou; Sotirios P Fortis; Konstantina A Tsante; Andreas G Tsantes; Efrosyni G Nomikou; Athanasia I Kapota; Dimitrios I Petras; Maria S Venetikou; Effie G Papageorgiou; Marianna H Antonelou; Anastasios G Kriebardis
Journal:  Biomolecules       Date:  2021-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.